JP Morgan Maintains Overweight on BridgeBio Pharma, Raises Price Target to $70

Benzinga · 09/03/2025 14:49
JP Morgan analyst Anupam Rama maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $55 to $70.